Identification and characterization of Klebsiella pneumoniae two lpxL lipid A late acyltransferases and their role in virulence. by Mills, Grant et al.
Identification and characterization of Klebsiella pneumoniae two lpxL
lipid A late  acyltransferases and their role in virulence.
Mills, G., Dumigan, A., Bengoechea, J. A., & Kidd, T. (2017). Identification and characterization of Klebsiella
pneumoniae two lpxL lipid A late  acyltransferases and their role in virulence. DOI: 10.1128/IAI.00068-17
Published in:
Infection and Immunity
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2017 American Society for Microbiology.
This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:09. Sep. 2018
1 
 
Identification and characterization of Klebsiella pneumoniae two lpxL lipid A late 1 
acyltransferases and their role in virulence. 2 
Grant Mills1, Amy Dumigan1, Timothy Kidd1,2,3, Laura Hobley1, José A. Bengoechea1 3 
1. Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, 4 
Belfast, United Kingdom 5 
2. School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, 6 
Australia 7 
3. Child Health Research Centre, The University of Queensland, Brisbane, Australia 8 
 9 
Corresponding author: 10 
Prof. José A. Bengoechea 11 
Wellcome-Wolfson Institute for Experimental Medicine,  12 
Queen's University Belfast 13 
The Wellcome Wolfson Building,   14 
97 Lisburn Road, Belfast, BT9 7BL   15 
Phone: +44 (0) 2890976357 16 
E-mail: j.bengoechea@qub.ac.uk 17 
Running title: Klebsiella lipid A late acyltransferase 18 
Keywords. lipid A, LpxL, Klebsiella, pathogenesis 19 
 20 
 21 
 22 
 23 
2 
 
ABSTRACT 24 
Klebsiella pneumoniae causes a wide range of infections, from urinary tract infections to 25 
pneumonia. The lipopolysaccharide is a virulence factor of this pathogen, although there are 26 
gaps in our understanding of its biosynthesis. Here we report the characterization of K. 27 
pneumoniae LpxL which encodes one of the enzymes responsible for late secondary acylation 28 
of immature lipid A molecules. Analysis of the available K. pneumoniae genomes revealed that 29 
this pathogen encodes two orthologues of Escherichia coli LpxL. Using genetic methods and 30 
mass spectrometry, we demonstrate that LpxL1 catalyses the addition of laureate and LpxL2 31 
the addition of myristate. Both enzymes acylated E. coli lipid A whereas only LpxL2 mediated 32 
K. pneumoniae lipid A acylation. We show that LpxL1 is negatively regulated by the two-33 
component system PhoPQ. The lipid A produced by lpxL2 mutant lacked the 2-34 
hydroxymyristate, palmitate, and 4-aminoarabinose decorations found in the lipid A 35 
synthesized by the wild type. The lack of 2-hydroxymiristate was expected since LpxO 36 
modifies the myristate transferred by LpxL2 to the lipid A. The absence of the other two 37 
decorations is most likely caused by downregulation of phoPQ and pmrAB expression. LpxL2-38 
dependent lipid A acylation protects Klebsiella from polymyxins, mediates resistance to 39 
phagocytosis, limits the activation of inflammatory responses by macrophages, and is required 40 
for pathogen survival in the waxmoth Galleria mellonella. Our findings indicate that LpxL2 41 
contribution to virulence is dependent on LpxO-mediated hydroxylation of the LpxL2-42 
transferred myristate. Our studies suggest that LpxL2 might be a candidate target for 43 
developing anti K. pneumoniae drugs. 44 
 45 
 46 
 47 
 48 
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INTRODUCTION 49 
Lipopolysaccharide (LPS) is the major constituent in the Gram-negative outer 50 
membrane and it is composed of three regions: the lipid A domain, the core oligosaccharide 51 
and the O-antigen polysaccharide. The canonical hexa-acylated lipid A structure is expressed 52 
by Escherichia coli K12 and consists of a β(1´-6)-linked disaccharide of glucosamine 53 
phosphorylated at the 1 and 4′ positions with  positions 2, 3, 2´, and 3´acylated with R-3-54 
hydroxymyristoyl groups, the so-called lipid IVA. The 2´and 3´R-3-hydroxymyristoyl groups 55 
are further acylated with laureate (C12) and myristate (C14) (Fig 1A) (1). Five enzymes are 56 
required to assemble the β,1′-6 linked disaccharide that is characteristic of all lipid A molecules 57 
whereas LpxK, KdtA, LpxL (HtrB) and LpxM (MsbB) catalyse the last four enzymatic steps 58 
to assemble the Kdo2-hexa-acylated lipid A (1). LpxK phosphorylates the 4′-position of the 59 
disaccharide 1-phosphate to form lipid IVa; next two Kdo residues are incorporated by the 60 
enzyme KdtA to generate the molecule Kdo2-lipid A IVA (Fig 1A). The last steps involve the 61 
addition of the secondary lauroyl and myristoyl residues to the distal glucosamine unit by LpxL 62 
and LpxM (Fig 1A), which require the Kdo disaccharide moiety in their substrates for activity 63 
(1). When E. coli is grown at 12oC, LpxP, the cold-temperature-specific late acyltransferase, 64 
acts in place of LpxL by adding palmitoleate (C16:1) (1). There is lipid A diversity among Gram-65 
negative bacteria. This is dependent on the type and length of fatty acids, on the presence of 66 
chemical moieties or even on the lack of groups such as phosphates or fatty acids from lipid A 67 
(1, 2).Well-characterized modifications comprise the addition of phosphoethanolamine (3), 4-68 
amino-4-deoxy-l-arabinose (4), palmitate (5), and hydroxylation by the Fe2+/α-ketoglutarate-69 
dependent dioxygenase enzyme (LpxO) (6).  These modifications provide resistance to stresses 70 
such as harsh pH and antimicrobial peptides (APs) (2). APs are directed to LPS on the bacterial 71 
surface by electrostatic interactions. Colistin (polymyxin E) and polymyxin B are two 72 
antimicrobials which share the interaction with the anionic LPS with mammalian APs (7). 73 
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Colistin is one of the last-line antimicrobials for Gram negative multi-drug resistant strains (8). 74 
Additionally, these lipid A changes may help pathogens to modulate the activation of host 75 
defense mechanisms by altering the activation of the TLR4/MD-2 receptor complex (9). 76 
Klebsiella pneumoniae is a capsulated Gram negative pathogen which causes a wide 77 
range of infections, from urinary tract infections to pneumonia, the latter being particularly 78 
devastating among immunocompromised patients (10, 11). Of particular concern is the 79 
increasing isolation of multidrug resistant strains worldwide hence narrowing the therapeutic 80 
options for the treatment of Klebsiella infections. However, and despite the clinical relevance, 81 
there is still scant evidence on K. pneumoniae pathogenesis at the molecular and cellular level.  82 
The polysaccharide sections of K. pneumoniae LPS had been extensively studied. The 83 
core and O-antigen polysaccharides from several Klebsiella strains were characterized 84 
chemically and genetically, and their contribution to virulence assessed in an animal infection 85 
model (12-22). In contrast, little attention has been given to K. pneumoniae lipid A 86 
biosynthesis. We and others have demonstrated that K. pneumoniae lipid A is hexa-acylated, 87 
the 2´and 3´R-3-hydroxymyristoyl groups being acylated with C14 (Fig 1B) (23-27). The 88 
enzymatic activity of K. pneumoniae LpxM, which catalyses the transfer of C14 to the 3´R-3-89 
hydroxymyristoyl group, has been experimentally confirmed (23, 26). Our laboratory has 90 
uncovered that K. pneumoniae lipid A could be decorated with palmitate, 4-amino-4-deoxy-l-91 
arabinose, phosphoethanolamine, and 2-hydroxymyristate (C14:OH) (Fig 1C) (23-25). The gene 92 
encoding for the acyltransferase pagP is required for the addition of palmitate to lipid A, the 93 
pmrHFIJKLM (arnBCADTEF) (hereafter pmrF operon) loci are required for the synthesis and 94 
addition of aminoarabinose to lipid A, eptA/pmrC is necessary for the modification of the lipid 95 
A with phosphoethanolamine whereas lpxO is responsible for modification of the 2′-linked 96 
secondary acyl chain with a hydroxyl group at the 2-position (Fig 1C) (23-25). We have 97 
demonstrated that these lipid A decorations provide resistance to APs (23-25), and the K. 98 
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pneumoniae mutants lacking them are attenuated for virulence in the mouse pneumonia model 99 
(23-25).  100 
The function of K. pneumoniae LpxL late acyl transferase has not been investigated 101 
yet. Based on the structure of the lipid A produced by the lpxM mutant (23, 26), the current 102 
widely-held belief is that K. pneumoniae LpxL catalyses the transfer of C14 to the 2´R-3-103 
hydroxymyristoyl group (Fig 1B). However, it has been reported the presence of hexa-acylated 104 
K. pneumoniae lipid A species which is consistent with the presence of C12 and C14 acylating 105 
the 2´and 3´R-3-hydroxymyristoyl groups, respectively (23, 26). Moreover, a recent report 106 
suggests that K. pneumoniae may encode two LpxL acyltransferases responsible for late 107 
secondary acylation of immature lipid A molecules (28). Altogether, these observations 108 
question the previously assigned function to the lipid A late acyltransferases, chiefly LpxL. 109 
The aim of this work was to provide mechanistic insights into the function of K. pneumoniae 110 
LpxL and to investigate its role in K. pneumoniae virulence.  111 
 112 
RESULTS 113 
K. pneumoniae encodes two lpxL late acyl transferases 114 
 In silico analysis of the available K. pneumoniae genomes revealed that this pathogen 115 
encodes two orthologues of E. coli LpxL. Analysis of the genome of the wild-type virulent K. 116 
pneumoniae strain 52.145 (Kp52145 herein, Table 1) revealed that LpxL1 (locus tag 117 
BN49_2155) and LpxL2 (locus tag and BN49_1538) are 77 and 71% identical, respectively to 118 
E. coli LpxL. Previously, we identified Kp52145 orthologue of E. coli LpxM (locus tag 119 
BN49_3476) and demonstrated it catalyses the transfer of C14 to the 3´R-3-hydroxymyristoyl 120 
group (23). Each Kp52145 LpxL acyltransferase was mutated to determine whether they 121 
contribute to the acylation of K. pneumoniae lipid A. Control experiments showed that the 122 
growth kinetics in both rich and in minimal media were similar between the wild-type and the 123 
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lpxL mutant strains. (Fig S1). We sought to determine whether capsule levels were affected in 124 
the lpxL mutants. This is an important control given the crucial role played by the K. 125 
pneumoniae capsule to thwart host defences (20, 29-35). The levels of surface attached capsule 126 
were not significantly different between lpxL1, lpxL2 mutant strains and the wild type (168 ± 127 
5.7 µg/109 CFUs, 170.5 ± 4.4 µg/109 CFUs and 176.4 ± 7.8 µg/109 CFUs, respectively; P>0.05 128 
for any comparison between the mutants and the wild type). 129 
Lipid A was extracted from the wild type and lpxL mutant strains using an ammonium 130 
hydroxide/isobutyric acid method and subjected to negative ion matrix-assisted laser 131 
desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. The lpxL1 mutant 132 
(strain 52145-∆lpxL1) produced a lipid A similar to that previously reported for the wild-type 133 
strain (23, 24) (Fig 2A and B). Lipid As contained predominantly hexa-acylated species of (a 134 
mass-to-charge ratio, m/z) m/z1824 corresponding to two glucosamines, two phosphates, four 135 
3-OH-C14, and two C14. Hexa-acylated species m/z1840 corresponds to two glucosamines, two 136 
phosphates, four 3-OH-C14, one C14 and one C14:OH. Other species detected were consistent 137 
with the addition of 4-amino-4-deoxy-l-arabinose (m/z131) or palmitate (m/z239) to the hexa-138 
acylated species (m/z1824) to produce lipid A species m/z1955 and m/z2063, respectively.  139 
In contrast, the lipid A produced by the lpxL2 mutant (strain 52145-∆lpxl2) (m/z1614) 140 
was consistent with a penta-acylated lipid A corresponding to two glucosamines, two 141 
phosphates, four 3-OH-C14, and one C14 (Fig 2C). The lipid A produced by the double mutant 142 
lpxL1-lpxL2 was similar to that of the lpxL2 mutant (Fig 2D). Complementation of the lpxL2 143 
single mutant and the double mutant lpxL1-lpxL2 with lpxL2 restored the production of wild-144 
type lipid A (Fig 2E and F) hence suggesting that LpxL2 is the acyltransferase responsible for 145 
the transfer of C14 to the acyl chain linked at the 2′-position of K. pneumoniae lipid A.  146 
To provide additional evidence that LpxL2 acylates the 2´-R-3-hydroxymyristoyl group 147 
with C14, we determined the lipid A produced by the E. coli lpxL deficient strain, BN1∆lpxL 148 
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(Table 1), harbouring lpxL2 cloned into pGEM–T Easy plasmid (pGEMTlpxL2Com) (Table 149 
1). BN1 strain produced bis-phosphorylated, hexa-acylated lipid A containing C12 and C14 (Fig 150 
S2A). In contrast, MALDI-TOF analysis of lipid A isolated from BN1∆lpxL yielded an 151 
expected peak at m/z1614 (Fig S2B) indicating bis-phosphorylated, penta-acylated lipid A 152 
lacking C12. However, mass spectrometry analysis of lipid A isolated from 153 
BN1∆lpxL/pGEMTlpxl2Com produced a peak at m/z1824 (Fig S2C), thereby demonstrating 154 
that LpxL2 catalyses the transfer of C14 to E. coli lipid A. 155 
Notably, no lipid A modifications were detected in the lipid A produced by the lpxL2 156 
mutant (Fig 2C). The lack of 2-hydroxymiristate was expected since LpxO modifies the C14 157 
transferred by LpxL2 to the 2´R-3-hydroxymyristoyl group (23, 25). However, we did not 158 
anticipate the lack of 4-amino-4-deoxy-l-arabinose and palmitate. To provide mechanistic 159 
insights, we sought to determine if the expressions of the pmrF operon and pagP were 160 
downregulated in the lpxL2 mutant background. To quantitatively assess the transcription of 161 
these loci we used two transcriptional fusions containing a promoterless luciferase firefly gene 162 
(lucFF) under the control of the relevant locus promoter region. Each fusion (pmrH::lucFF 163 
and pagP::lucFF; Table 1) was introduced into Kp52145, 52145-∆lpxL2, and 52145-164 
∆lpxL2Com2, and then luciferase activity was measured. Figure 3 shows that the activity of 165 
the pmrH::lucFF and pagP::lucFF fusions were significantly lower in the lpxL2 mutant 166 
background than in the wild type. Complementation of the lpxL2 mutant restored the activities 167 
of the transcriptional fusions to wild-type levels (Fig 3). The fact that the two component 168 
systems PhoPQ and PmrAB regulate the expression of the pmrF operon and pagP in K. 169 
pneumoniae (24) prompted us to evaluate whether the expression of phoPQ and pmrAB are 170 
affected in the lpxL2 mutant. RT-qPCR experiments showed that phoPQ and pmrAB mRNA 171 
levels were significantly lower in the lpxL2 mutant than in the wild type which were not 172 
different than those found in the complemented strain (Fig 3). Altogether, these findings 173 
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suggest that the absence of 4-amino-4-deoxy-l-arabinose and palmitate modifications in the 174 
lipid A produced by the lpxL2 mutant is most likely caused by downregulation of phoPQ and 175 
pmrAB expression, the positive transcriptional regulators of the pmrF operon and pagP. 176 
Heterologous expression of LpxL1 in E. coli revealed its C12 transferase activity. 177 
Sequence analysis of K. pneumoniae lpxL1 gene did not reveal any frameshift or point 178 
mutations consistent with a deleterious effect. Therefore, we investigated the activity of K. 179 
pneumoniae LpxL1 by determining the lipid A produced by E. coli BN1∆lpxL harbouring 180 
lpxL1 cloned into pGEM–T Easy plasmid (pGEMTlpxL1Com). Interestingly, K. pneumoniae 181 
LpxL1 restored the production of wild-type E. coli lipid A in BN1∆lpxL hence indicating that 182 
LpxL1 transfers C12 to the 2´-R-3-hydroxymyristoyl group (Fig 4A). This was also true in the 183 
Klebsiella background because MALDI-TOF analysis of lipid A extracted from 52145-184 
∆lpxL1∆lpxL2/pGEMTlpxL1Com yielded a peak at m/z1797 indicating the presence of bis-185 
phosphorylated, hexa-acylated lipid A containing C12 and C14 (Fig 4B). Further, this lipid A 186 
species was modified with palmitate (m/z2036) (Fig 3B). However, single-copy chromosomal 187 
complementation of the double mutant with Tn7-T-Km-lpxL1 did not yield the peak at 188 
m/z1797. Control experiments confirmed that E. coli BN1∆lpxL was complemented using this 189 
construct (Fig 4D). Collectively, these results indicate that the lack of LpxL1-dependent 190 
acylation in K. pneumoniae lipid A cannot be attributed to a general deficient function of the 191 
enzyme.  192 
PhoPQ negatively regulated lpxL1 193 
To explain why LpxL1-dependent lipid A was not observed in K. pneumoniae, we 194 
speculated, among other possibilities, that lpxL1 expression could be repressed in Klebsiella. 195 
To monitor transcription of lpxL1 and lpxL2, two transcriptional fusions were constructed in 196 
which a promoterless lucFF gene was under the control of the acyltransferases promoters. 197 
These fusions were introduced into wild-type Klebsiella and the amount of light was 198 
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determined. The expression of lpxL1::lucFF was lower than that of lpxL2::lucFF (Fig 5A). 199 
Likewise, when lpxL mRNA levels were analyzed by RT-qPCR, transcripts levels of lpxL1 200 
were lower than those of lpxL2 (Fig 5B). These results gave initial support to our hypothesis 201 
that the expression of lpxL1 might be repressed in K. pneumoniae.  202 
In silico analysis of lpxL1 promoter region revealed the presence of a PhoP box-like 203 
sequence (36) 120 bp upstream of the initiation codon. In contrast, no PhoP consensus motif 204 
was found in the lpxL2 promoter region. Since PhoPQ governs K. pneumoniae loci implicated 205 
in lipid A remodelling (24), we hypothesized that PhoPQ represses the expression of lpxL1. 206 
Indeed, the activity of the transcriptional fusion lpxL1::lucFF was higher in the phoQ mutant 207 
background than in the wild-type one (Fig 5C). Complementation of the phoQ mutant restored 208 
the activity of the transcriptional fusion to wild-type levels. Similar results were obtained when 209 
the lpxL1 mRNA levels were analysed (Fig 5). Of note, neither the activity of lpxL2::lucFF 210 
nor lpxL2 mRNA levels were affected in the phoQ mutant background (Fig S3).  211 
These findings led us to hypothesize that LpxL1-dependent lipid A acylation should be 212 
apparent in the phoQ mutant. Supporting this hypothesis, MALDI-TOF analysis of lipid A 213 
purified from the phoQ mutant yielded a peak at m/z1797 (Fig 5E). Complementation of the 214 
phoQ mutant restored the production of wild-type lipid A (Fig 5F). m/z1797 species in the 215 
phoQ mutant was dependent on LpxL1 activity since the peak was absent in the lipid A from 216 
the double mutant lpxL1-phoQ (Fig 5G).  217 
On the whole, these results are consistent with the notion that PhoPQ negatively 218 
regulates LpxL1-dependent lipid A acylation.  219 
Resistance to antimicrobial peptides and Klebsiella LpxL2 late acyltransferase 220 
We sought to determine whether Lpx2-dependent acylation protects K. pneumoniae 221 
from polymyxins. The lpxL2 mutant showed increased sensitivity to both polymyxins (Table 222 
2). Similar findings were obtained when the susceptibility to polymyxins was evaluated after 223 
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1-h challenge with the peptides (3 µg/ml) (Fig 6).  Complementation fully restored resistance 224 
of the lpxL2 mutant to wild-type levels (Fig 6), indicating that LpxL2-dependent acylation is 225 
associated with resistance to polymyxins. 226 
In K. pneumoniae, the lipid A modifications with 4-amino-4-deoxy-l-arabinose and 2-227 
hydroxymiristate mediate resistance to polymyxins (23-25). The fact that the lipid A of the 228 
lpxL2 mutant lacked both modifications (Fig 3) may suggest that LpxL2 contribution to APs 229 
resistance could be indirect. The MIC to polymyxins of the lpxO mutant were the same as those 230 
of the lpxL2 mutant whereas the MIC to polymyxins of the pmrF mutant were not significantly 231 
different than those of the wild-type strain (Table 2). The lpxO mutant also showed an increase 232 
susceptibility to polymyxins after 1 h challenge (Fig 6). Complementation of the lpxO mutant 233 
restored the MIC value to wild- type level, suggesting that the increase susceptibility of the 234 
lpxL2 mutant to polymyxins is associated with the lack of 2-hydroxymiristate. Control 235 
experiments confirmed that the lipid A produced by the lpxO mutant still contained species 236 
m/z1955 and m/z2063 consistent with the addition of 4-amino-4-deoxy-l-arabinose and 237 
palmitate to the hexa-acylated species (m/z1824), respectively (Fig S4). The growth kinetics in 238 
both rich and in minimal media were similar between the wild-type, the lpxO mutant and the 239 
lpxL mutant strains (Fig S1). 240 
Phagocytosis of K. pneumoniae lpxL2 mutant 241 
Phagocyte-mediated killing of the lpxL2 mutant was analysed using the whole blood 242 
phagocytosis assay which measures bacterial viability following exposure to whole human 243 
blood (Fig. 7). The assay showed that the lpxL2 mutant was recovered in significantly lower 244 
numbers than the wild type. Interestingly, the survival of the lpxO mutant was not significantly 245 
different than that of the lpxL2 mutant (Fig 6; P > 0.05) whereas viability of the pmrF and pagP 246 
mutants did not differ from that of the wild-type strain (Fig S5). Complementation of the lpxO 247 
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mutant restored the survival to wild-type levels, indicating that the decrease survival of the 248 
lpxL2 mutant is associated with the lack of 2-hydroxymiristate in the lipid A (Fig 7). 249 
Inflammation induced by K. pneumoniae lpxL2 mutant 250 
The lipid A is bound by the TLR-4/MD-2 complex hence leading to the activation of 251 
MyD88 and TRIF-dependent innate signalling pathways resulting in inflammation and 252 
clearance of the infection. Not surprisingly, TLR4-governed responses are essential to clear K. 253 
pneumoniae infections (37, 38). We sought to determine the responses induced by the lpxL2 254 
mutant in macrophages. Figure 8 shows that the lpxL2 mutant induced higher levels of the 255 
MyD88-dependent cytokines TNFα and IL6, and the TRIF-dependent ones RANTES and 256 
MCP-1 in the supernatants of bone marrow derived macrophages than those triggered by the 257 
wild type. The lpxL2 complemented strain induced similar levels of cytokines than the wild-258 
type strain (Fig 8). The lpxO mutant also induced higher levels of cytokines than the wild type, 259 
and the levels were not significantly different than those induced by the lpxL2 mutant (P >0.05, 260 
Fig 8). Complementation of the lpxO mutant restored cytokine production to wild-type levels 261 
in infected macrophages (Fig 8), suggesting that the increase inflammatory response triggered 262 
by the lpxL2 mutant is due to the lack of 2-hydroxymiristate in the lipid A. 263 
Virulence of K. pneumoniae lpxL mutants in the Galleria. mellonela model. 264 
The G. mellonella infection model has been recently established to model the virulence 265 
of K. pneumoniae (30). Importantly, a strong correlation between virulence in Galleria and 266 
mouse (pneumonia model) has been demonstrated (30). To determine the virulence of the lpxL 267 
mutants, we injected equivalent numbers of CFU from wild-type, mutants, and complemented 268 
strains into G. mellonella and monitored bacterial killing over time. No mortality was observed 269 
in PBS-injected Galleria (Fig 9). After 72 h, only 20% of the larvae injected with the wild type 270 
and lpxL1 mutant survived. In contrast, 40% of the larvae injected with the lpxL2 and lpxL1-271 
lpxL2 mutants survived (P <0.05 for any comparison versus wild-type survival). 272 
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Complementation of these strains with lpxL2 restored the virulence to wild-type levels 273 
indicating that LpxL2-dependent acylation is important for K. pneumoniae survival and 274 
virulence in invertebrates. Interestingly, the killing induced by the lpxO mutant was similar to 275 
that triggered by the lpxL2 mutant (P > 0.05) suggesting that the reduced virulence of the lpxL2 276 
mutants is due to the absence of 2-hydroxymiristate in the lipid A. Control experiments showed 277 
that pmrF and pagP mutants were as virulent as the wild-type strain (Fig S6). 278 
 279 
DISCUSSION 280 
The work described in this study demonstrates that K. pneumoniae encodes two LpxL 281 
late-acyltransferases; LpxL1 catalyses the addition of laureate (C12) and LpxL2 the addition of 282 
myristate (C14). Our data establishes that both enzymes catalyse the transfer of these fatty-acids 283 
to the lipid A in the E. coli background whereas only LpxL2 mediates K. pneumoniae lipid A 284 
acylation when Klebsiella is grown in standard laboratory medium. This study demonstrates 285 
that LpxL2 plays an important role in K. pneumoniae infection biology since LpxL2-dependent 286 
lipid A acylation protects the pathogen from APs, mediates resistance to phagocytosis and 287 
limits the activation of inflammatory responses by macrophages. Our results also show that 288 
deletion of lpxL2 attenuates K. pneumoniae virulence in the G. mellonella infection model. The 289 
fact that there is a strong correlation between the virulence of K. pneumoniae in G. mellonella 290 
and mammalian models (30) suggests that LpxL2-mediated lipid A acylation is important for 291 
K. pneumoniae virulence beyond invertebrates. 292 
 The synthesis of hexa-acylated lipid A occurs via a nine-step enzymatic pathway, which 293 
is generally well conserved throughout all gram-negative bacteria (1). In Enterobacteriaceae, 294 
the last steps of lipid A biosynthesis are dependent on LpxL and LpxM late acyltransferases 295 
which utilize acyl-ACPs exclusively as donors (1). lpxL and lpxM display significant sequence 296 
similarity among Enterobacteriaceae although they may catalyze the transfer of a different 297 
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fatty acid. In this context, it was unexpected to note that K. pneumoniae encodes two 298 
orthologues of E. coli LpxL on the chromosome. Our genetic and biochemical analysis 299 
conclusively assigned the function of LpxL1 and LpxL2 as laureate and myristate 300 
acyltransferases, respectively. Initially we were puzzled by the lack of LpxL1-mediated lipid 301 
A acylation in the K. pneumoniae background. However, the fact that we observed LpxL1-302 
dependent lipid A species m/z1797 in the double mutant lpxL1-lpxL2 only when lpxL1 was 303 
encoded in a high-copy number plasmid led us to hypothesize that lpxL1 expression is 304 
repressed in K. pneumoniae. Indeed, we uncovered that LpxL1 is negatively regulated by the 305 
two-component system PhoPQ. Interestingly, we have recently demonstrated that this is also 306 
true in K. pneumoniae resistant to colistin arising from mutational inactivation of the mgrB 307 
regulatory gene (25). MgrB is a negative feedback regulator of PhoPQ (25, 39)and, therefore, 308 
mgrB mutation is associated with upregulation of phoPQ resulting in increased expression of 309 
lpxO, pagP, pmrC and the pmrF operon, which in turn facilitates lipid A modifications with 2-310 
hydroxymyristate, 4-amino-4-deoxy-l-arabinose, phosphoethanolamine and palmitate (25). As 311 
anticipated, these modifications were absent in the lipid A produced by the double mgrB-312 
phoPQ mutant but, and in perfect agreement with the findings reported in this work, we 313 
detected LpxL1-dependent species m/z1797 in the lipid A produced by this mutant (25).  314 
Our findings are reminiscent of those reported for Shigella flexneri and E. coli O157:H7 315 
that encode two lpxM (40-42). However, in stark contrast to Klebsiella, in both of these 316 
pathogens one of the two LpxM paralogues is plasmid-encoded, both enzymes catalyse the 317 
transfer of the same fatty acid to the lipid A, and PhoPQ is a positive regulator (40-42).  318 
The fact that PhoPQ is activated by different signals in vivo and in vitro raises the 319 
intriguing notion that K. pneumoniae may regulate the acylation of its 2´R-3-hydroxymyristoyl 320 
group in response to environmental signals. Furthermore, our data suggests that the presence 321 
of lipid A species m/z1797 may indicate an environment where PhoPQ activity is repressed. 322 
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We have reported recently the detection of lipid A species m/z1797 in K. pneumoniae that 323 
reached the spleens of intranasally infected mice (23) hence suggesting that PhoPQ activity 324 
may be diminished in the spleens of infected mice. On the other hand, it is interesting to 325 
consider why K. pneumoniae may prefer LpxL2-mediated acylation versus LpxL1-controlled 326 
acylation.  Although there are potentially several explanations it is worth noting that in K. 327 
pneumoniae LpxO-dependent hydroxylation only occurs in the C14 transferred to the 2´R-3-328 
hydroxymyristoyl group by LpxL2 (this work and (23)), and we have demonstrated that 329 
deletion of lpxO attenuates K. pneumoniae virulence in vivo (23, 30). The fact that PhoPQ is a 330 
positive regulator of lpxO (23) further underscores the importance of PhoPQ-mediated negative 331 
regulation of lpxL1.  332 
It was unexpected to observe the lack of 4-amino-4-deoxy-l-arabinose, and palmitate 333 
decorations in the lipid A produced by the lpxL2 mutant. Notably, this phenotype was specific 334 
for lpxL2 inactivation since we did not observe any effect on lipid A decorations of the lipid 335 
As produced by lpxL1 and lpxM mutants (this work and (23, 26)). This is in stark contrast to 336 
E. coli and S. typhimurium where lpxM inactivation results in loss of 4-amino-4-deoxy-l-337 
arabinose (43). We cannot rule that the lack of myristoylation in K. pneumoniae lipid A impairs 338 
the enzymatic activity of PmrK/ArnT and PagP responsible for transferring 4-amino-4-deoxy-339 
l-arabinose and palmitate to the lipid A respectively. However, our data demonstrates that 340 
transcription of the phoPQ and pmrAB, two component systems which govern the expression 341 
of pagP and the pmrF/arn operon (24), were downregulated in the lpxL2 mutant with a 342 
concomitant downregulation of the expressions of pagP and pmrF/arn operon. Interestingly, 343 
we did not observe an increase of lpxL1 transcription in the lpxL2 mutant background (Fig S7) 344 
despite the decrease of phoPQ expression in this mutant. This result may indicate that the low 345 
levels of phoP in the lpxL2 mutant background are enough to repress lpxL1 expression but are 346 
not sufficient to increase the expressions of pagP and the pmrF operon. However, by no means 347 
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do we rule out that there might be other regulatory systems controlling lpxL1 expression. Future 348 
research efforts will be devoted to characterize in detail lpxL1 expression and to identify any 349 
additional putative lpxL1 regulator. 350 
Another novel finding of this work is that the lpxL2 mutant elicited higher inflammatory 351 
responses than the wild type. This observation challenges the conventional wisdom that 352 
Enterobacteriaceae late acyltransferases lipid A mutants elicit limited activation of 353 
inflammatory responses (40, 44, 45). Mechanistically, our data is consistent with the notion 354 
that lpxL2 mutant-induced heightened inflammation is due to the lack of LpxO-mediated lipid 355 
A modification. This is in perfect agreement with our recent work demonstrating that K. 356 
pneumoniae LPS containing 2-hydroxymyristate is less inflammatory than that lacking this 357 
modification (23). Our data also suggested that lpxL2 contribution to polymyxin resistance, 358 
phagocytosis evasion and virulence in G. mellonella infection model are dependent on LpxO-359 
mediated hydroxylation of the LpxL2-transferred myristate. These findings are consistent with 360 
previous studies demonstrating the role of K. pneumoniae LpxO-mediated lipid A modification 361 
on AP resistance, and phagocytosis evasion by professional phagocytes (macrophages and 362 
amoeba) (23, 25, 46). Altogether, this evidence sustains the notion that LpxO-controlled lipid 363 
A hydroxylation plays a major role in K. pneumoniae strategies to counter host defence 364 
mechanisms. To generalize that the presence of a hydroxyl group on a lipid A secondary acyl 365 
chain is a bacterial mechanism to evade innate immune defences warrants further studies. 366 
However, and providing additional support to this notion, hydroxylation on the 3′-linked 367 
secondary acyl chain of Vibrio cholerae also promotes resistance to APs (47). The fact several 368 
other Gram negative pathogens synthesize lipid A species that possess a hydroxyl group on a 369 
secondary acyl chain (Salmonella, Pseudomonas, Legionella, Acinetobacter, Vibrio) (6, 48-50) 370 
might suggest that this lipid A modification is a conserved microbial anti-immune mechanism.  371 
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 Finally, it is worth discussing the clinical implications of our findings. K. pneumoniae 372 
has been singled out recently as an urgent threat to human health by the World Health 373 
Organization, the US Centers for Disease Control and Prevention and the UK Department of 374 
Health due to the increase number of multidrug-resistant isolates. K. pneumoniae infections are 375 
particularly a problem among neonates, elderly and immunocompromised individuals within 376 
the healthcare setting, but this organism is also responsible for a significant number of 377 
community-acquired infections including pneumonia and sepsis (11, 51). The evidence 378 
presented in this work warrants further investigation of the lpxL2 gene product as a novel target 379 
for antimicrobial therapy. Even though these compounds targeting LpxL2 might not inhibit the 380 
growth of Klebsiella since the growth kinetics of lpxL2 and lpxO mutants were not affected, 381 
our data suggest that they will render the bacteria susceptible to APs and will also increase 382 
inflammatory responses. Both actions should facilitate the clearance of the pathogen from the 383 
airways, which might be further enhanced with the aid of antibiotics. However, the clinical 384 
utility of any molecule against lpxL2, when and if developed, remains to be determined.  385 
 386 
MATERIAL AND METHODS 387 
Bacterial strains and growth conditions 388 
Bacterial strains and plasmids used in this study are listed in Table 1. Strains were 389 
grown in lysogeny broth (LB) medium at 37ᵒC on an orbital shaker (180 rpm). When 390 
appropriate, antibiotics were added to the growth medium at the following concentrations: 391 
ampicillin (Amp), 100µg/ml; kanamycin (Km), 50µg/ml; chloramphenicol (Cm), 25µg/ml; and 392 
trimethoprim (Tp) at 100µg/ml. 393 
To assess the growth of K. pneumoniae strains, bacteria were grown at 37ᵒC in 5 ml of 394 
LB medium on an orbital shaker (180 rpm) overnight, and 5 µl of this culture were added to 395 
250 µl of either LB or M9 minimal medium.  Absorbance readings at OD of 600 (OD600) were 396 
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measured at 20 minute intervals over a 24 hour period using a Bioscreen C Automated 397 
Microbial Growth Analyzer (MTX Lab Systems, Vienna, VA, USA). A total of 5 independent 398 
growth curves were obtained for each strain. 399 
K. pneumoniae mutant construction 400 
Primers for mutant construction (Table S1) were designed based on the whole genome 401 
sequence of K. pneumoniae 52.145 (GenBank Accession No. FO834906.1). Two sets of 402 
primers were used to amplify two lpxL1 fragments, Lpxl1UP and LpxL1DOWN by PCR using 403 
Ex Taq Polymerase (Takara). These fragments were annealed at their overlapping regions, 404 
amplified as a single fragment and cloned into pGEM-T Easy (Promega) to obtain 405 
pGEMTlpxl1.  Similar approach was followed to obtain pGEMTlpxl2. A kanamycin cassette 406 
was obtained as a BamHI fragment from pGEMTFRTKM (24) and cloned into BamHI-407 
digested pGEMTΔlpxl-1 and pGEMTΔlpxl-2 to generate pGEMTΔlpxl1Km and 408 
pGEMTΔlpxl2Km respectively. The lpxl-1Km and lpxl-2Km fragments (~3.5kb each) were 409 
subsequently obtained by NotI digestion, gel purified and cloned into NotI-digested pJTOOL-410 
1.  pJTOOL-1 is a suicide vector that carries a R6K origin of replication, an oriT sequence for 411 
conjugational transfer, and a Cm resistance marker (52). It also carries the sacB gene that 412 
mediates sucrose sensitivity as a positive selection for the excision of the vector after double 413 
crossing-over (52). pJTOOL-1-lpxl-1Km and pJTOOL-1-lpxl-2Km were transformed into E. 414 
coli β2163 from which the plasmids were mobilized into K. pneumoniae 52.145 by 415 
conjugation. Transconjugants were selected after growth on LB plates supplemented with Cm 416 
at 37°C. A total of 10 merodiploids were serially diluted in PBS, spread on LB plates without 417 
NaCl containing 6% sucrose and incubated at 25ᵒC. The recombinants that survived 10% 418 
sucrose were checked for their antibiotic resistance and the appropriate replacement of the 419 
wild-type alleles by the mutant ones was confirmed by PCR. Recombinants selected were 420 
named 52145∆lpxL1Km and 52145∆lpxL2Km. The Km cassettes were excised by FLP-421 
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mediated recombination using plasmid pFLP2 (53) as we have previously described (24). The 422 
mutants selected were named 52145-∆lpxl1 and 52145-∆lpxl2.  423 
The lpxL1-lpxl2 double mutant, strain 52145-∆lpxL1lpxL2, was obtained by mobilizing 424 
pJTOOL-1-lpxL2Km into 52145∆lpxL1. The replacement of the wild-type allele by the mutant 425 
one was done as previously described and confirmed by PCR. 426 
The lpxL1-phoQ double mutant, strain 52145-∆lpxL1∆phoQ, was obtained by 427 
mobilizing pMAKSACBΔphoQGB (24) into 52145-∆lpxL1. The lpxO mutant, strain 52145-428 
∆lpxO, was constructed by mobilising pMAKSACΔlpxO (25) into K. pneumoniae 52.145. The 429 
replacement of the wild-type alleles by the mutant one was done as previously described and 430 
confirmed by PCR. 431 
Complementation of K. pneumoniae mutants 432 
To complement the lpxL mutants, DNA fragments containing the putative promoter 433 
region and coding region of lpxl1 and lpxL2 were PCR-amplified using Ex Taq Polymerase, 434 
gel purified and cloned into pGEM-T Easy to obtain pGEMTlpxl1Com and pGEMTlpxl2Com. 435 
These plasmids were then electroporated into K. pneumoniae and E. coli mutant strains, and 436 
clones were selected after growth on LB plates supplemented with Amp at 37°C. For single-437 
copy chromosomal complementation, PvuII fragments from pGEMTlpxL1Com and 438 
pGEMTlpxL2Com were gel purified and cloned into SmaI-digested pUC18R6kTminiTn7-T-439 
Km (54) to obtain pUC18R6kTminiTn7-T-Km-lpxL1Com and pUC18R6kTminiTn7-T-Km-440 
lpxL2Com, respectively. The pSTNSK-Tp plasmid, which contains the transposase tnsABCD 441 
necessary for Tn7 transposition (55), was electroporated into K. pneumoniae lpxL mutants. The 442 
pUC18R6kTminiTn7-T-Km-lpxL1 and pUC18R6kTminiTn7-T-Km-lpxL2 plasmids were 443 
then mobilised by conjugation into the mutants harbouring pSTNSK-Tp. Colonies were 444 
checked for resistance to Km and sensitivity to Amp. As the Amp resistance cassette is located 445 
outside of the Tn7 region of the vector, Amp sensitivity denotes the integration of the Tn7 446 
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derivative at the attTn7 site instead of incorporation of the vector into the chromosome. 447 
Confirmation of integration of the Tn7 transposon at the established attTn7 site located 448 
downstream of the glmS gene was verified by PCR as we have previously described (25, 56). 449 
pSTNSK-Tp from the recipient strains was cured by growing bacteria at 37 °C due to the 450 
plasmid thermosensitive origin of replication pSC101. Plasmid removal was confirmed by 451 
susceptibility to Tp.  452 
E. coli lpxL mutant construction  453 
The bacterial mutant BN1∆lpxL was created using the Red recombinase system method 454 
(57). The strain BN1 is an lpxT, eptA and pagP mutant (58). A Km cassette flanked by FRT 455 
sites was PCR amplified using the pKD4 plasmid as a template (57). The primers used for 456 
amplification incorporated homologous extensions to the lpxL gene (Table S1). The PCR 457 
product was gel purified, treated with DpnI, and 1µg of the DNA was electroporated into E. 458 
coli BN1 harbouring the pKD46 plasmid (57). Mutants were selected on LB agar containing 459 
Km and a recombinant in which the wild-type allele was replaced by the mutant one was 460 
selected. The appropriate replacement of the wild-type allele by the mutant one was confirmed 461 
by PCR and the Km cassette was subsequently excised by FLP-mediated recombination using 462 
plasmid pFLP2. The strain generated was named BN1∆lxpL. 463 
Construction of reporter fusions 464 
DNA fragments containing the promoter regions of the lpxL1, and lpxL2 genes were 465 
amplified by PCR using Phusion polymerase (NEB), EcoRI-digested, gel-purified and cloned 466 
into EcoRI-SmaI-digested pGPL01 suicide vector (59). This vector contains a promoterless 467 
firefly luciferase gene (lucFF) and an R6K origin of replication. Plasmids in which lucFF was 468 
under the control of the Klebsiella promoters were identified by restriction digestion analysis 469 
and named pGPLKpnlpxL1, and pGPLKpnlpxL2 respectively. Reporter plasmids 470 
pGPLKpnPmrH and pGPLKpnPagP have been described previously (24, 25).  471 
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Plasmids were conjugated into the different K. pneumoniae strains, and strains in which 472 
the suicide vector was integrated into the genome by homologous recombination were selected. 473 
Correct insertion of the vectors into the chromosome was confirmed by PCR using the relevant 474 
lucFF_check and promoter sequence primers (Table S1). 475 
Luciferase activity 476 
The reporter strains were grown on an orbital shaker (180 rpm) at 37ᵒC until the 477 
exponential phase and harvested (3,000 x g, 20 min, 22°C). The bacteria were then washed 478 
once with sterile PBS and adjusted to OD600 1.0. A 100 µl aliquot of the bacterial suspension 479 
was mixed with 100 µl of luciferase assay reagent (1 mM D -luciferin [Synchem] in 100 mM 480 
citrate buffer [pH 5]. Luminescence was immediately measured with a Glomax 20/20 481 
Luminometer (Promega) and expressed as relative light units (RLU).  All measurements were 482 
carried out in quintuplicate on at least three separate occasions. 483 
Capsule purification and quantification  484 
Bacterial strains were grown overnight at 37ᵒC overnight in 3 ml LB medium, and 485 
viable counts were determined by dilution plating. Bacteria were then harvested (3,000 x g, 20 486 
min, 22°C) and the cell pellet was resuspended in 500 µl of sterile water. Samples were then 487 
treated with 1% 3-(N,N-Dimethyltetradecylammonio)propanesulfonate (Sigma; in 100 mM 488 
citric acid, pH 2.0) at 50ᵒC for 20 minutes. The bacterial debris was pelleted (3000 x g, 10 489 
minutes, 22°C) and 250 µl of supernatant were transferred into a clean 15 ml glass tube. The 490 
capsule polysaccharide was ethanol precipitated at -20ᵒC for 20 minutes and recovered by 491 
centrifugation (9000 x g, 10 minutes, 4°C). Pellets were dried (5 minutes, 90ᵒC) and 492 
resuspended in 200 µl of sterile water. Capsule was quantified by determining the concentration 493 
of uronic acid in the samples, using a modified carbazole assay, as described by Rahn and 494 
Whitfield (60). All extractions and quantifications were carried out on three independent 495 
occasions. 496 
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Isolation and analysis of lipid A 497 
Lipid A’s were extracted using an ammonium hydroxide/isobutyric acid method (61) 498 
and subjected to negative-ion matrix-assisted laser desorption ionization time-of-flight 499 
(MALDI-TOF) mass spectrometry analysis. Briefly, bacteria were grown in 10 ml of LB 500 
medium until the exponential phase, washed once with PBS and the pellet resuspended in 400µl 501 
of isobutyric acid–1 M ammonium hydroxide (5:3 [vol/vol]) in a screw-cap test tube. Sample 502 
was then incubated at 100°C for 2 h with occasional vortexing before being cooled in ice water 503 
and centrifuged (2,000 x g for 15 min). The supernatant was transferred to a new tube, diluted 504 
with an equal volume of water, and lyophilized. The lyophilized material was washed twice 505 
with 400 µl of methanol and centrifuged (2,000 x g for 15 min). The insoluble lipid A was 506 
solubilized in 50 to 100 µl of chloroform-methanol-water (3:1.5:0.25 [vol/vol/vol]). To analyse 507 
the samples, a few microliters of lipid A suspension (1 mg/mL) were desalted with a few grains 508 
of ion-exchange resin (Dowex 50W-X8; H+) in a 1.5-mL microcentrifuge tube. A 1 μL aliquot 509 
of the suspension (50–100 μL) was deposited on the target and covered with the same amount 510 
of dihydroxybenzoic acid matrix (Bruker Daltonics Inc.) dissolved acetonitrile-0.1% 511 
trifluoroacetic acid (1:2[vol/vol/vol]). Different ratios between the samples and 512 
dihydroxybenzoic acid were used when necessary. Analyses were performed on a Bruker 513 
autoflex® speed TOF/TOF mass spectrometer (Bruker Daltonics Inc.) in negative reflective 514 
mode with delayed extraction. The ion-accelerating voltage was set at 20 kV. Each spectrum 515 
was an average of 300 shots. A peptide calibration standard (Bruker Daltonics Inc.) was used 516 
to calibrate the MALDI-TOF. Further calibration for lipid A analysis was performed externally 517 
using lipid A extracted from E. coli strain MG1655 grown in LB medium at 37°C. 518 
Interpretation of the negative-ion spectra is based on earlier studies showing that ions with 519 
masses higher than 1,000 gave signals proportional to the corresponding lipid A species present 520 
in the preparation (23, 24, 62). Important theoretical masses for the interpretation of peaks 521 
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found in the present study are: C14:OH , 226; C12 , 182; C14 , 210; 4-amino-4-deoxy-l-arabinose, 522 
131; and C16 , 239.  Spectra are representative of at least three independent lipid A extractions. 523 
Infection of Galleria mellonella larvae 524 
G. mellonella larvae were acquired from UK Waxworms Ltd. and kept at 21ᵒC in 525 
darkness. Larvae were used within 3 days of receipt. Larvae of approximately 250-350 mg 526 
were selected for the experiments. 527 
Infections were performed as our laboratory has described with minor modifications 528 
(30). Briefly, bacteria were grown in 5 ml LB medium until exponential phase and harvested 529 
(3,000 x g, 20 min, 22°C). Bacteria were subsequently washed once with 10 mM PBS (pH 6.5) 530 
and diluted in PBS to an OD600 of 1.0 which corresponds approximately to 5 x10
8 CFU/ml. 531 
After surface disinfection using ethanol (70% v/v), larvae were injected with 10 µl of the 532 
bacterial suspension containing approximately 1x105 CFU into the last right pro-leg using a 533 
Hamilton syringe with a 30 gauge needle. A group of ten larvae were injected with 10 µl of 534 
PBS in parallel to ensure that death is not due to the injection trauma. Larvae were placed in 535 
9.2 cm Petri-dishes and kept at 37ºC in the dark.  Insects were considered dead when they did 536 
not respond to physical stimuli. Larvae were examined for pigmentation and time of death was 537 
recorded. Assays were allowed to proceed for only 3 days as pupa formation could occasionally 538 
be seen by day 4. At least three independent experiments (30 larvae per strain) were performed. 539 
RNA isolation and RT-qPCR 540 
Bacteria were grown in 5 ml LB medium until an OD600 of 1.0. An equal volume of 541 
RNAlater (Ambion) was added to the culture and incubated at room temperature (22ᵒC) for 30 542 
minutes. Bacteria were then centrifuged (3000g, 20 min, 22ᵒC) and the supernatant removed. 543 
Total RNA was extracted from bacterial pellets using TRIzol reagent (Ambion). Extracted 544 
RNA was DNase treated using DNase I (Roche) and precipitated using sodium acetate 545 
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(Ambion) and ethanol. RNA was quantified using a Nanovue Plus (GE Healthcare Life 546 
Sciences). 547 
cDNA was obtained by retrotranscription of 1µg of total RNA using a commercial M-548 
MLV Reverse Transcriptase (Invitrogen) and random primers (Invitrogen). 20 ng of cDNA 549 
were used as a template in a 20 µl reaction containing KapaSYBR Fast qPCR Kit (Kapa 550 
Biosystems) and primer mix. RT-qPCR analyses were performed using an Mx3005P 551 
instrument (Agilent) using the following thermocycling protocol:  95°C for 3min for hot-start 552 
polymerase activation, followed by 40 cycles of 95°C for 10s and 56°C for 30s. SYBR green 553 
dye fluorescence was measured at 521 nm. Relative quantities of mRNAs were obtained using 554 
the comparative threshold cycle (ΔΔCT) method by normalizing to rpoD. cDNAs were 555 
obtained from three independent extractions of RNA and each one amplified by RT-qPCR  556 
Antimicrobial peptide susceptibility assays 557 
Bacteria were grown at 37ᵒC in 5ml of LB medium and harvested (3000 x g, 20 min, 558 
22ᵒC) in the exponential growth phase. Bacteria were then washed once with PBS and a 559 
suspension containing 4x104 CFU/ml was prepared in 10 mM PBS (pH 6.5), 1% tryptone soy 560 
broth (Oxoid), and 100 mM NaCl. Aliquots of the suspension (25 µl) were mixed in 0.2 ml 561 
tubes with the appropriate antibiotic at a final concentration of 3µg/ml to give a final volume 562 
of 30 µl. After 1 hour of incubation at 37ᵒC, 15 µl were plated on LB agar and colony counts 563 
were determined after incubation at 37oC for 24 h. The results were expressed as percentages 564 
of the colony count of bacteria not exposed to antibiotics. All experiments were performed with 565 
duplicate samples on three independent occasions.   566 
Minimum Inhibitory Concentrations (MICs) were determined by Etest® (BioMérieux) 567 
according to the manufacturer’s instructions. MIC testing was performed on two independent 568 
occasions. 569 
Whole Blood Phagocytosis Assay  570 
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Bacteria were grown at 37ᵒC in 5ml of LB medium on an orbital shaker (180 rpm) until 571 
the exponential phase and harvested (3,000 x g, 20 min, 22°C). Bacteria were subsequently 572 
washed once and diluted in PBS to an OD600 of 1.0. Further dilutions in PBS were made to 573 
obtain 1x107 CFU/100µl bacterial suspensions. 300 µl of fresh human blood (used within 30 574 
minutes of removal) was mixed with 1x107 CFU/100µl bacterial suspension and incubated at 575 
37ᵒC on an orbital shaker (180 rpm) for 3 hours. After incubation, dilutions were plated to 576 
obtain viable counts. The bacterial counts recovered were then divided by the initial counts. 577 
Experiments were performed using blood from three individual blood donors, and for each 578 
blood sample each strain was tested in duplicate. Ethical approval for use of blood from healthy 579 
volunteers to study bacterial killing was from the Research Ethics Committee of the School of 580 
Medicine, Dentistry and Biomedical Sciences (Queen’s University Belfast). 581 
Macrophage infections. 582 
Immortalised murine bone marrow-derived macrophages (iBMDMs) (BEI Resources, 583 
NIAID, NIH: Macrophage Cell Line Derived from Wild Type Mice, NR-9456) were grown in 584 
Dulbecco’s Modified Eagle Medium (DMEM; Gibco® 41965) supplemented with 10% heat-585 
inactivated foetal calf serum (FCS), 100 U/ml penicillin, and 0.1 mg/ml streptomycin (Gibco) 586 
at 37°C in a humidified 5% CO2 incubator. Cells were routinely tested for Mycoplasma 587 
contamination. For infections, iBMDMs were seeded at 2.5x105 cells per well in 96-well plates.  588 
To prepare the inoculi for infections, bacteria were grown until exponential phase in 5 589 
ml LB, supplemented with the appropriate antibiotics when required, at 37ᵒC on an orbital 590 
shaker (180 rpm).  Bacteria were recovered by centrifugation (3000 x g, 20 min, 22ᵒC), washed 591 
once with PBS, and diluted in PBS to an OD600 of 1.0 which corresponds approximately to 5 592 
x108 CFU/ml.  This bacterial suspension was UV-irradiated at 1 Joule for 20 minutes, and 593 
bacterial killing was confirmed by plating in LB.  Bacterial suspensions were stored at -80ᵒC. 594 
iBMDMs were challenged with 1x105 bacteria for 6 hours, and supernatants collected for 595 
25 
 
cytokine determination. Experiments were performed in duplicate and repeated three 596 
independent times. 597 
Cytokine quantification 598 
Cytokines in the supernatants were determined using a Luminex® multiplex assays 599 
(R&D Systems, Abingdon, UK) as recommended by the manufacturer. Analysis were 600 
performed using a Bio-Plex 100 with xMAP Technology (Hertfordshire, UK).  601 
Statistical analysis. 602 
Statistical analyses were performed using one-way analysis of variance (ANOVA) with 603 
Bonferroni contrasts or the one-tailed t test or, when the requirements were not met, by the 604 
Mann-Whitney U test. P < 0.05 was considered statistically significant. Survival analyses were 605 
undertaken using the Log-rank (Mantel-Cox) test with Bonferroni correction for multiple 606 
comparisons (α=0.008). The analyses were performed using Prism4 for PC (GraphPad 607 
Software). 608 
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FIGURE LEGENDS 840 
Figure 1. Synthesis of hexa-acylated lipid A in E. coli and K. pneumoniae.  841 
(A) In E. coli, LpxL transfers laurate (C12) group from an acyl carrier protein (ACP) onto the 842 
R-2′-hydroxymyristate acyl chain of Kdo2-lipid IVA. Subsequently, LpxM-dependent addition 843 
of myristate (C14) onto the R-3′-hydroxymysristate residue results in the synthesis of hexa-844 
acylated Kdo2-lipid A. (B) In K. pneumoniae, LpxL (which we named LpxL2 in this work) 845 
and LpxM transfer myristate onto the R-3′-hydroxymysristate residue to complete the synthesis 846 
of hexa-acylated Kdo2-lipid A. (C) Proposed lipid A structures follow previously reported 847 
structures for K. pneumoniae (23-27). The modifications and genes responsible for each of 848 
them are indicated in the figure. 849 
Figure 2. K. pneumoniae LpxL2 acylates the 2´-R-3-hydroxymyristoyl group with C14 850 
Negative ion MALDI-TOF mass spectrometry spectra of lipid A purified from:  851 
(A) K. pneumoniae 52.145 (Kp52145), (B) 52145-ΔlpxL1 (lpxL1), (C) 52145-ΔlpxL2 (lpxL2), 852 
(D) 52145-ΔlpxL1ΔlpxL2 (lpxL1-lpxL2), (E) 52145-ΔlpxL2Com2 (lpxL2Com2) and (F) 853 
52145-ΔlpxL1ΔlpxL2Com2 (lpxL1-lpxL2Com2) strains. Data represent the mass to charge 854 
(m/z) ratios of each lipid A species detected and are representative of three extractions. 855 
Figure 3. Deletion of lpxL2 reduces the transcription of phoPQ and pmrAB.  856 
Activity of the pmrH (A), and pagP (B) promoters in K. pneumoniae 52.145 (Kp52145, white 857 
bars), 52145-ΔlpxL2 (lpxL2, black bars), and 52145-ΔlpxL2Com2 (lpxL2Com2, grey bars), 858 
carrying lucFF transcriptional fusions. Values (expressed in relative luminescence units, 859 
[RLU]) are presented as the mean ± SD of three independent experiments measured in 860 
quintuplicate.  861 
The transcription levels of phoP (C) and pmrA (D) in K. pneumoniae 52.145 (Kp52145, white 862 
bars), 52145-ΔlpxL2 (lpxL2, black bars), and 52145-ΔlpxL2Com2 (lpxL2Com2, grey bars) 863 
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were determined by RT-qPCR and are shown relative to the expression levels in wild-type 864 
bacteria (white bars). Results represent means ± SD. 865 
**, P<0.01;***, P<0.001; n.s., not significant versus Kp52145 determined using one-way 866 
analysis of variance (ANOVA) with Bonferroni contrasts. 867 
Figure 4. K. pneumoniae LpxL2 acylates the 2´-R-3-hydroxymyristoyl group with C12 868 
Negative ion MALDI-TOF mass spectrometry spectra of lipid A purified from:  869 
(A) E. coli BN1ΔlpxL complemented with K. pneumoniae lpxL2 870 
(BN1ΔlpxL/pGEMTLpxL2Com), (B) 52145-ΔlpxL1ΔlpxL2 complemented with K. 871 
pneumoniae lpxL1 cloned into pGEM-TEasy plasmid (ΔlpxL1ΔlpxL2/pGEMTLpx1Com), (C) 872 
52145-ΔlpxL1ΔlpxL2 complemented with K. pneumoniae lpxL2 cloned into Tn7 transposon 873 
(ΔlpxL1ΔlpxL2::Tn7LpxL1, (D) E. coli BN1ΔlpxL complemented with K. pneumoniae lpxL1 874 
cloned into Tn7 transposon (BN1ΔlpxL:: Tn7LpxL1) strains. Data represent m/z ratios of each 875 
lipid A species detected and are representative of three extractions. 876 
Figure 5. PhoPQ negatively regulates K. pneumoniae lpxL1. 877 
(A) Activity of the lpxL1 and lpxL2 promoters in K. pneumoniae 52.145 (Kp52145) carrying 878 
lucFF transcriptional fusions. Values (expressed in relative luminescence units, [RLU]) are 879 
presented as the mean ± SD of three independent experiments measured in quintuplicate.  880 
(B) The transcription levels of lpxL1 and lpxL2 in K. pneumoniae 52.145 (Kp52145) were 881 
determined by RT-qPCR and are shown relative to the expression levels in wild-type bacteria. 882 
Results represent means ± SD. 883 
(C) Activity of the lpxL1 promoter in K. pneumoniae 52.145 (Kp52145), 52145-∆phoQGB 884 
(phoQ), and 52145-∆phoQGBCom (phoQCom), carrying lucFF transcriptional fusions. Values 885 
(expressed in relative luminescence units, [RLU]) are presented as the mean ± SD of three 886 
independent experiments measured in quintuplicate.  887 
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(D) The transcription levels of lpxL1 in K. pneumoniae 52.145 (Kp52145), 52145-∆phoQGB 888 
(phoQ), and 52145-∆phoQGBCom (phoQCom) were determined by RT-qPCR and are shown 889 
relative to the expression levels in wild-type bacteria. Results represent means ± SD. 890 
Negative ion MALDI-TOF mass spectrometry spectra of lipid A purified from: (E) 52145-891 
∆phoQGB (phoQ), (F) 52145-∆phoQGBCom (phoQCom) and (G) 52145-∆lpxL1∆phoQGB 892 
(lpxL1-phoQ). Data represent m/z ratios of each lipid A species detected and are representative 893 
of three extractions. 894 
*, P<0.05;**, P<0.01; ***, P<0.001; n.s., not significant versus Kp52145 or between the 895 
indicated comparisons determined using one-way analysis of variance (ANOVA) with 896 
Bonferroni contrasts. 897 
Figure 6. Deletion lpxL2 decreases K. pneumoniae resistance to polymyxins. 898 
Percent survival of K. pneumoniae 52.145 (Kp52145), 52145-∆lpxL2 (lpxL2), 52145-899 
∆lpxL2Com2 (lpxL2Com2), 52145-∆lpxO (lpxO), and   52145-∆lpxOCom (lpxOCom) 900 
following one hour exposure to: (A) polymyxin B, and (B) colistin. Values are presented as the 901 
mean ± SD of three independent experiments measured in duplicate. **, P< 0.01; versus 902 
Kp52145 determined using one-way ANOVA with Bonferroni contrasts. 903 
Figure 7. Deletion lpxL2 increases human phagocytes-mediated killing of K. pneumoniae.  904 
300 µl of fresh human blood (from three different donors) were mixed with 1x107 CFUs of K. 905 
pneumoniae 52.145 (Kp52145), 52145-∆lpxL2 (lpxL2), 52145-∆lpxL2Com2 (lpxL2Com2), 906 
52145-∆lpxO (lpxO), and   52145-∆lpxOCom (lpxOCom) and incubated at 37ᵒC for 3 hours. 907 
The bacterial counts recovered were then divided by the initial counts. Experiments were 908 
performed with duplicate samples on three independent occasions.   909 
**, P<0.01; n.s., not significant versus Kp52145 determined using one-way ANOVA with 910 
Bonferroni contrasts. 911 
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Figure 8. lpxL2 deletion results in upregulation of inflammatory responses in 912 
macrophages upon infection. 913 
TNFα (A), IL6 (B), RANTES (C), and MCP-1 (D) secretion by iBMDM macrophages 914 
stimulated for 6 hours with UV-killed K. pneumoniae 52.145 (Kp52145), 52145-∆lpxL2 915 
(lpxL2), 52145-∆lpxL2Com2 (lpxL2Com2), 52145-∆lpxO (lpxO), and   52145-∆lpxOCom 916 
(lpxOCom). *, P<0.05; **, p<0.01; n.s., not significant versus Kp52145 determined using one-917 
way ANOVA with Bonferroni contrasts. 918 
Figure 9. K. pneumoniae lpxL2 mutant displays decrease virulence in the G. mellonella 919 
waxworm infection model. 920 
Percent survival of G. mellonella over 72 hours post-infection with 105 organisms of: K. 921 
pneumoniae 52.145 (Kp52145), 52145-∆lpxL1 (lpxL1), 52145-∆lpxL2 (lpxL2), 52145-922 
∆lpxL1∆lpxL2 (lpxL1-lpxL2), 52145-∆lpxO (lpxO), 52145-∆lpxL1∆lpxL2Com2 (lpxL1-923 
lpxL2Com2), 52145-∆lpxOCom (lpxOCom), and 52145-∆lpxL2Com2 (lpxL2Com2). Thirty 924 
larvae were infected in each group. Level of significance was determined using the log-rank 925 
(Mantel-Cox) test with Bonferroni correction for multiple comparisons.  926 
 927 
 928 
 929 
 930 
 931 
 932 
 933 
 934 
Table 1. Strains and plasmids used in this study. 935 
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Bacterial strain or plasmid Genotype or Comments Source or 
reference  
Strains   
Escherichia coli   
   
C600 thi thr leuB tonA lacY supE Laboratory 
collection 
SY327 l (lac pro) argE (Am) rif nalA recA56 (l pir) Laboratory 
collection 
β2163 (F-) RP4-2-Tc::Mu DdapA::(erm-pir) [KmREmR] (63) 
BN1 W3110 ΔeptA ΔlpxT ΔpagP (58) 
BN1∆lpxL BN1, ∆lpxL::FRT; the lpxL gene was inactivated This work 
BN1∆lpxL::Tn7-T-Km-lpxL1 BN1∆lpxL,  Tn7-T-Km-lpxL1 integrated into 
attTn7 site, KmR 
This work 
MG1655 F- λ- ilvG rfb-50 rph-1 Laboratory 
collection 
   
Klebsiella pneumoniae   
   
52.145 Clinical isolate; serotype O1:K2; sequence type 
ST66 
(64) 
52145-∆lpxL1 Kp52145, ∆lpxL1::FRT; the lpxL1gene was 
inactivated 
This study 
52145-∆lpxL2 Kp52145, ∆lpxL2::FRT; the lpxL2 gene was 
inactivated 
This study 
52145-∆lpxL1∆lpxL2 Kp52145, ∆lpxL1::FRT, ∆lpxL2::FRT; the lpxL1 
and lpxL2 genes were inactivated 
This study 
52145-∆lpxL2Com2 Kp52145, ∆lpxL2::FRT;  Tn7-T-Km-lpxL2 
integrated into attTn7 site, KmR 
This study 
52145-∆lpxL1∆lpxL2Com2 Kp52145, ∆lpxL1::FRT, ∆lpxL2::FRT;  Tn7-T-Km-
lpxL2 integrated into attTn7 site, KmR 
This study 
52145-∆lpxL1∆lpxL2Com1 Kp52145, ∆lpxL1::FRT, ∆lpxL2::FRT;  Tn7-T-Km-
lpxL` integrated into attTn7 site, KmR 
This study 
52145-∆lpxO Kp52145, ∆lpxO::FRT; the lpxO gene was 
inactivated 
This study 
52145-∆lpxOCom Kp52145, ∆lpxO::FRT,   Tn7-Cm_KpnLpxOCom  
integrated into attTn7 site  
This study 
52145-∆phoQGB Kp52145, ∆phoQ::Km-GenBlock; the phoQ gene 
was inactivated; KmR  
(24) 
52145-∆phoQGBCom Kp52145, ∆phoQ::Km-GenBlock;  Tn7-
Cm_KpnPhoPQCom  integrated into attTn7 site; 
CmR, KmR  
(23) 
52145-∆lpxL1∆phoQGB  Kp52145, ∆lpxL1:;FRT, ∆phoQ::Km-GenBlock; 
the lpxL1 and phoQ genes were inactivated; KmR  
This study 
52145-∆pmrF Kp52145, ∆pmrF::FRT; the pmrF gene was 
inactivated 
(24) 
52145-∆pagP  Kp52145, ∆pagP; the pagP gene was inactivated (25) 
   
Plasmids   
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 936 
 937 
 938 
pGEM-T Easy Cloning plasmid; AmpR Promega 
pGEMTFRTKm Km cassette source for mutagenesis flanked by 
BamHI-FRT sites 
(24) 
pJTOOL-1 λpir-based suicide vector with NotI cloning site. 
Derived from pDS132; CmR 
(52) 
pSTNSK-Tp pSTNSK-Tp containing a transposase for Tn7 
insertion; KmR, TmpR 
(55) 
pKD46 λ phage redγβα, arabinose inducible; AmpR (57) 
pUC18R6KT-mini-Tn7TKm pUC18R6KT-mini-Tn7T complementation vector; 
AmpR, KmR 
(54) 
pGP-Tn7-Cm pGP-Tn7 complementation vector; AmpR, CmR (55) 
pFLP2 Plasmid encoding FLP to remove cassettes between 
FRT sites, sacB gene; TpR 
(53) 
pGPL01 Firefly luciferase (lucFF) transcriptional fusion 
suicide vector, R6K origin of replication; AmpR 
(59) 
pGEMTlpxL1 pGEM-T Easy containing ΔlpxL1; AmpR This study 
pGEMTlxpL2 pGEM-T Easy containing ΔlpxL2; AmpR This study 
pGEMTlpxL1Km pGEM-T Easy containing ΔlpxL1Km; KmR, AmpR This study 
pGEMTlxpL2Km pGEM-T Easy containing ΔlpxL2Km; KmR, AmpR This study 
pJTOOL1-lpxL1Km  pJTOOL-1 containing ΔlpxL1Km;  KmR ,CmR This study 
pJTOOL1-lpxL2Km  pJTOOL-1 containing ΔlpxL2KM;  KmR , CmR This study 
pMAKSACΔlpxO pMAKSACB containing ΔlpxO::Km-GenBlock; 
CmR, KmR 
(25) 
pMAKSACBΔphoQGB pMAKSACB containing ΔphoQ::Km-GenBlock; 
CmR, KmR 
(24) 
pGEMTlxpL1Com pGEM-T Easy containing lpxL1 gene for 
complementation; AmpR 
This study 
pGEMTlxpL2Com pGEM-T Easy containing lpxL2 gene for 
complementation; AmpR 
This study 
pUC18R6kTminiTn7-T-Km-
lpxL1 
pUC18R6kTminiTn7-T-Km containing lpxL1 gene 
for complementation; AmpR, KmR 
This study 
pUC18R6kTminiTn7-T-Km-
lpxL2  
pUC18R6kTminiTn7-T-Km containing lpxL2 gene 
for complementation; AmpR, KmR 
This study 
pGP-Tn7-Cm_KpnLpxOCom pGP-Tn7-Cm containing lpxO gene for 
complementation; AmpR, CmR 
(23) 
pGP-Tn7-Cm_KpnPhoPQCom pGP-Tn7-Cm containing phoPQ operon for 
complementation; AmpR, CmR 
(23) 
pGPLKpnProlpxL1 pGPL01 containing the lpxL1 promoter region; 
AmpR 
This study 
pGPLKpnProlpxL2 pGPL01 containing the lpxL2 promoter region; 
AmpR 
This study 
pGPLKpnProPmrH pGPL01 containing the pmrH promoter region; 
AmpR 
(24) 
pGPLKpnProPagP pGPL01 containing the pagP promoter region; 
AmpR 
(25) 
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Table 2. MIC to polymyxin B and colistin for K. pneumoniae strains. 939 
 MIC (µg/ml) 
Strains Polymyxin B Colistin 
Kp52145 0.5 0.25 
52145-∆lpxL1 0.5 0.25 
52145-∆lpxL2 0.125* 0.094* 
52145-∆lpxL1∆lpxL2 0.125* 0.094* 
52145-∆lpxL2Com2 0.5 0.25 
52145-∆lpxL1∆lpxL2Com2 0.5 0.25 
52145-∆lpxO 0.125* 0.094* 
52145-∆lpxOCom 0.5 0.25 
52145-∆pmrF n.t. 0.25 
52145-∆pagP n.t. 0.25 
 940 
*, MIC significantly different (P < 0.05; one-tailed t test) from MIC for the wild-type strain. 941 
n.t; not tested. Experiments were repeated two independent times. 942 
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Figure S1. Growth kinetics of K. pneumoniae lpxO and
lpxLmutants.
Growth kinetics of K. pneumoniae 51.245 (Kp52145, red),
52145-ΔlpxL1 (lpxL1, black), 52145-ΔlpxL2 (lpxL2, grey),
52145-ΔlpxL1ΔlpxL2 (lpxL1-lpxL2, blue), and 52145-ΔlpxO
(lpxO, yellow) cultured in LB broth (LB) and 2% glucose M9
minimal media supplemented with thiamine and MgSO4
(M9) over 24 hours at 370C. Values are presented as the
mean ± SD of five independent experiments.
 
 
 
 
 
 
Table S1. Primers used in this study. 
Method and 
target gene 
      Primer Sequence (5’–3’) 
   
Mutagenesis and 
complementations 
  
   
K. pneumoniae   
   
       lpxL1 KpnLpxL1UpF GCG ATG TTA CTG ACG TTG CC 
 
 KpnLpxL1UpR 1CGG ATC CGC GCG TGG ATG AAC 
AAG ATC G 
 
 KpnLpxL1DownF 1CGG ATC CGT TTT CTC GGG GAA 
GCA GAG C 
 
 KpnLpx1DownR GTC CTG CAT CAT TTC CAC GG 
 
 KpnLpxL1ComF GCC GGT TAA AAA GCA GCC AA 
 
 KpnLpxL1ComR AGG AAA TAA ACG GCG GGC AT 
 
    lpxL2 KpnLpxL2UpF GCC CAC GTC GCA GAA TAG AT 
 
 KpnLpxL2UpR 1CGG ATC CGA AAT TCA GCC CTT 
ACG CTG G 
 
 KpnLpxL2DownF 1CGG ATC CGC TTT AAG ACC CGC 
CCG GAA G 
 
 KpnLpxL2DownR ACC GTC GCG ATG TAC TCA AG 
 
 KpnLpxL2ComF TGA GCG CTG TAA ACG TAG CA 
 
 KpnLpxL2ComR TAG CCT TCA GTC AGG CCC TT 
 
    lpxO Kpn_LpxO_check_F CTC GGG GTT GTA CCA GAT CG 
 
 Kpn_LpxO_check_R TTA ACG GCG GCT TTT TCC TG 
 
   phoQ Kpn_phoQ_check_F 
 
GTT CGA TAA AGT CGG GCC AG 
 Kpn_phoQ_check_R 
 
CCG GAA TTC CGA ACA TCT CCC GGA 
TAT CG 
Tn7 insertion Kpn_glmS_Up GCG ACA ACT GTT GCG ACG GTG 
 
 Kpn_glmS_Down TGG CTT ATC ACG TCG CGC TG 
 
 Tn7_Left ATT AGC TTA CGA CGC TAC ACC C 
 
 Tn7_Right CAC AGC ATA ACT GGA CTG ATT TC 
 
E. coli   
   
  lpxL EcoliLpxLF 
 
CCT TCC GGG CGT GTT TTA AAG CGA 
CGG TGT AAC CAC ATA TGT GTA GGC 
TGG AGC TGC TTC 
 EcoliLpxLR 
 
GCA CTG CTT CAT CCG CGT TAT TGG 
TTA ACC TGG TTG GGT ACA TAT GAA 
TAT CCT CCT TAG 
 EcoliLpxL_check_ F 
 
GCA CAC TAA TTA TGC GCC CG 
 
 Km.cassette.checkK1R 
 
CAG TCA TAG CCG AAT AGC CT 
 
 Km.cassette.checkKtR 
 
CGG CCA CAG TCG ATG AAT CC 
 
 Ecoli_LpxL_check_F1 
 
TTT GCT GTG GTA ATG CCG GA 
 
 Ecoli_LpxL_check_R1 
 
TTT TGG TTG CGG GCG AAA AA 
 
 Ecoli_glmS_Up 
 
TCG ACT GGG CGT ACA AAA CC  
 
 Ecoli_glmS_Down 
 
CGG GAA ACC ATA CCG GAG TT   
 
 Tn7_Left 
 
ATT AGC TTA CGA CGC TAC ACC C  
 Tn7_Right CAC AGC ATA ACT GGA CTG ATT TC 
 
Reporter plasmids   
   
K. pneumoniae    
   
   lucFF lucFF_check_F 
 
GAA GCG AAG GTT GTG GAT CT 
 lucFF_check_R 
 
AAC CGG GAG GTA GAT GAG AT 
   
  lpxL1 Kpn_Prom.LpxL1_F 
 
TTT CGC CCG ACG CTT CAT AA 
 
 Kpn_Prom.LpxL1_R 
 
2GGA ATT CTT CGA AAT GGC CCA 
CCT CAT 
 
  lpxL2 Kpn_Prom.LpxL2_F 
 
2GGA ATT CTG TGA TGG ATA AGC 
TGG CCG 
 
 Kpn_Prom.LpxL2_R 
 
GTA ATT GCA CCA GCA GCC AC 
 
   
qPCR   
   
   
lpxl1 Kpn_LpxL1_qPCR_F 
 
GGC GGC AGG ATA ATC AGT TC 
 
 Kpn_LpxL1_qPCR_R 
 
AAA GGC GAA GTG GTG TGG TA 
 
lpxl2 Kpn_LpxL2_qPCR_F 
 
CGA CGA TTG TGC CGT TTG TT 
  
 Kpn_LpxL2_qPCR_R 
 
GCA GCC ACA TGT ATT GCT CG 
 
phoP Kpn_PhoP_qPCR_F 
 
GCG GTT ACG GAT CAG GGT TT 
 
 Kpn_PhoP_qPCR_R 
 
TAC GTC ACC AAG CCT TTC CA 
 
pmrA Kpn_pmrA_qPCR_F 
 
CCT TCA TCT TCC ACC GCC AT 
 
 Kpn_pmrA_qPCR_R 
 
CTG GCG ATG CGA CGT TAA TC 
 
1. BamHI site underlined; 2. EcoRI site underlined 
 
